…I don't believe [Teva] would have submitted an ANDA [if] the drug had been found to be so different from the branded.
What did Teva have to lose by trying? Whatever up-front money Teva paid to ItalFarmaco in 2002 or 2003 was probably de minimis for a company of Teva’s size.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”